What about chemoprevention for melanoma?

Current Opinion in Oncology

Volumn 18, Issue 2, 2006, Pages 180-184

  Demierre, Marie France ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoprevention strategy; Melanoma; Strong scientific rationale

Indexed keywords

ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EPIGALLOCATECHIN GALLATE; GENISTIN; GREEN TEA EXTRACT; IMIQUIMOD; NONSTEROID ANTIINFLAMMATORY AGENT; PERILLYL ALCOHOL; POLYPHENOL DERIVATIVE; RESVERATROL; SORAFENIB; STATINE DERIVATIVE;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VERRUCA VULGARIS;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; CLINICAL TRIALS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 33646705598     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000208792.22442.d2     Document Type: Review

References (48)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Robinson JK, Rigel DS, Amonette RA. Trends in sun exposure knowledge, attitudes, and behaviors: 1986 to 1996. J Am Acad Dermatol 1997; 37:179-186.
3. Robinson JK, Rigel DS, Amonette RA. Summertime sun protection used by adults for their children. J Am Acad Dermatol 2000; 42:746-753.
4. Geller AC, Colditz G, Oliveria S, et al. Use of sunscreen, sunburning rates, and tanning bed use among more than 10 000 US children and adolescents. Pediatrics 2002; 109:1009-1014.
5. Demierre MF, Nathanson L. Chemoprevention of melanoma: An unexplored strategy. J Clin Oncol 2003; 21:158-165.
6. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 2002; 62:5119-5125.
7. Follen M, Vlastos AT, Meyskens FL Jr, et al. Why phase II trials in cervical chemoprevention are negative: what have we learned? Cancer Causes Control 2002; 13:855-873.
8. Viner JL, Umar A, Hawk ET. Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am 2002; 31:971-999.
9. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-1155.
10. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005; 97:481-488.
11. Meyskens FL, Szabo E. How should we move the field of chemopreventive agent development forward in a productive manner? Recent Results Cancer Res 2005; 166:113-124. A thoughtful commentary on the challenges that lie in moving the field of chemoprevention forward.
12. Brenner DE, Gescher AJ. Cancer chemoprevention: lessons learned and future directions. Br J Cancer 2005; 93:735-739. An insightful mini-review on lessons learned in cancer chemoprevention.
13. Demierre MF, Sondak VK. Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Crit Rev Oncol Hematol 2005; 53:225-239. A comprehensive review of the rationale for chemoprevention of melanoma.
14. Demierre MF, Sondak VK. Chemoprevention of melanoma: theoretical and practical considerations. Cancer Control J 2005; 12:219-222.
15. Demierre MF, Merlino G. Chemoprevention of melanoma. Curr Oncol Rep 2004; 6:406-413.
16. Merlino G, Noonan FP. Modeling gene-environment interactions in malignant melanoma. Trends Mol Med 2003; 9:102-108.
17. Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806-812.
18. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95:1878-1890.
19. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005; 24:165-183. An important review on B-Raf and melanoma.
20. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
21. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62:6997-7000.
22. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19-20.
23. Reifenberger J, Knobbe CB, Sterzinger AA, et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004; 109:377-384.
24. Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005; 103:788-792.
25. Demierre MF, Higgins PDR, Gruber S, et al. Statins and cancer prevention. Nat Rev Cancer 2005; 5:930-942.
26. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-3151.
27. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001; 1:142-150.
28. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002; 15:7335-7342.
29. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23:363-398.
30. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005; 104:879-890. An important study that provides a scientific rationale for the use of curcumin in melanoma chemoprevention.
31. F'Guyer S, Afaq F, Mukhtar H. Photochemoprevention of skin cancer by botanical agents [review]. Photodermatol Photoimmunol Photomed 2003; 19:56-72.
32. Nihal M, Ahmad N, Mukhtar H, Wood GS. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005; 114:513-521. This study provides a rationale for the use of EGCG in melanoma chemoprevention.
33. Wei H, Saladi R, Lu Y, et al. Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutr 2003; 133 (Suppl. 1):3811S-3819S.
34. Russo A, Cardile V, Lombardo L, et al. Genistin inhibits UV light-induced plasmid DNA damage and cell growth in human melanoma cells. J Nutr Biochem 2005; August 17 [Epub ahead of print].
35. Meyskens FL, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res 2004; 10:2581-2583.
36. Millen AE, Tucker MA, Hartge P, et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13:1042-1051. An important case-control study that investigated the relationship between melanoma and dietary factors.
37. Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 2004; 134 (Suppl.):3479S-3485S.
38. Bianchini F, Vainio H. Wine and resveratrol: mechanisms of cancer prevention? Eur J Cancer Prev 2003; 12:417-425.
39. Yang S, McNulty S, Meyskens FL Jr. During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro. Pigment Cell Res 2004; 17:74-83.
40. Hsieh TC, Wang Z, Hamby CV, Wu JM. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun 2005; 334:223-230.
41. Harris RE, Beebe-Donk J, Namboodiri KK. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 2001; 8:655-657.
42. Drazen JM. COX-2 inhibitors - a lesson in unexpected problems [comment]. N Engl J Med 2005; 352:1131-1132. An important commentary on lessons learned with COX-2 inhibitors.
43. Goulet AC, Einsphar JG, Alberts DS, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003; 2:713-718 [erratum appears in Cancer Biol Ther 2004; 3:139].
44. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005; 141:510-514.
45. Hesling C, D'Incan M, Mansard S, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004; 150:761-767.
46. Armstrong WB, Taylor TH, Meyskens FL Jr. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 2003; 12:589-592.
47. Hawk ET, Umar A, Lubet RA, et al. Can animal models help us select specific compounds for cancer prevention trials? Recent Results Cancer Res 2005; 166:71-87. An excellent review on strategies to improve on the selection of specific compounds for cancer prevention trials.
48. Meyskens FL Jr, Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev 2005; 14:1366-1369.